This research provides a quantitative analysis of the fibroblast-to-myofibroblast transition (FMT), a critical process in ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of ...

MELBOURNE, Australia I 19, 2024 I Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its ...

The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in ...

Telix Pharmaceuticals Ltd. is expanding its theranostic pipeline with new assets targeting fibroblast activation protein (FAP). The company has entered into asset purchase and exclusive worldwide ...

NOVEL molecular regulators of rheumatoid arthritis (RA) inflammation were presented as part of a plenary abstract session at ...

Pathology and radiology giant Sonic Healthcare (ASX:SHL) says it is emerging from its post-pandemic malaise, with revenue ...

FibroBiologics (FBLG) announced the filing of a patent application with the United States Patent and Trademark Office covering methods ...

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...

Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it has expanded its leadership team with the appointments of Jan ...

Mestag Therapeutics ("Mestag"), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it has expanded ...